Human IPSC Modeling of Heart Disease for Drug Development

Overview

Journal Cell Chem Biol

Publisher Cell Press

Specialty Biochemistry

Date 2021 Mar 19

PMID 33740432

Citations 28

Authors

Anna P Hnatiuk

Francesca Briganti

David W Staudt

Mark Mercola

Affiliations

Soon will be listed here.

Abstract

Human induced pluripotent stem cells (hiPSCs) have emerged as a promising platform for pharmacogenomics and drug development. In cardiology, they make it possible to produce unlimited numbers of patient-specific human cells that reproduce hallmark features of heart disease in the culture dish. Their potential applications include the discovery of mechanism-specific therapeutics, the evaluation of safety and efficacy in a human context before a drug candidate reaches patients, and the stratification of patients for clinical trials. Although this new technology has the potential to revolutionize drug discovery, translational hurdles have hindered its widespread adoption for pharmaceutical development. Here we discuss recent progress in overcoming these hurdles that should facilitate the use of hiPSCs to develop new medicines and individualize therapies for heart disease.

Citing Articles

Ethanol exposure during differentiation of human induced pluripotent stem cells reduces cardiomyocyte generation and alters metabolism.

Man K, Fu L, Lane A, Harris F, Reid O, Armand L Life Sci. 2025; 364:123434.

PMID: 39892862 PMC: 11834986. DOI: 10.1016/j.lfs.2025.123434.

Reporter Alleles in hiPSCs: Visual Cues on Development and Disease.

Cotta G, Teixeira Dos Santos R, Costa G, Lacerda S Int J Mol Sci. 2024; 25(20).

PMID: 39456792 PMC: 11507014. DOI: 10.3390/ijms252011009.

Construction of Thick Myocardial Tissue through Layered Seeding in Multi-Layer Nanofiber Scaffolds.

You Y, Xu F, Liu L, Chen S, Ding Z, Sun D Polymers (Basel). 2024; 16(18).

PMID: 39339128 PMC: 11435929. DOI: 10.3390/polym16182664.

Creating cell-specific computational models of stem cell-derived cardiomyocytes using optical experiments.

Yang J, Daily N, Pullinger T, Wakatsuki T, Sobie E PLoS Comput Biol. 2024; 20(9):e1011806.

PMID: 39259757 PMC: 11460686. DOI: 10.1371/journal.pcbi.1011806.

MicroBundlePillarTrack: A Python package for automated segmentation, tracking, and analysis of pillar deflection in cardiac microbundles.

Kobeissi H, Gao X, DePalma S, Ewoldt J, Wang M, Das S ArXiv. 2024; .

PMID: 39184538 PMC: 11343223.

References

Vazao H, Rosa S, Barata T, Costa R, Pitrez P, Honorio I . High-throughput identification of small molecules that affect human embryonic vascular development. Proc Natl Acad Sci U S A. 2017; 114(15):E3022-E3031. PMC: 5393190. DOI: 10.1073/pnas.1617451114. View

Onakpoya I, Heneghan C, Aronson J . Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016; 14:10. PMC: 4740994. DOI: 10.1186/s12916-016-0553-2. View

Chintalgattu V, Rees M, Culver J, Goel A, Jiffar T, Zhang J . Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013; 5(187):187ra69. PMC: 3833098. DOI: 10.1126/scitranslmed.3005066. View

Del Alamo J, Lemons D, Serrano R, Savchenko A, Cerignoli F, Bodmer R . High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta. 2016; 1863(7 Pt B):1717-27. PMC: 4885786. DOI: 10.1016/j.bbamcr.2016.03.003. View

Ulmer B, Stoehr A, Schulze M, Patel S, Gucek M, Mannhardt I . Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. Stem Cell Reports. 2018; 10(3):834-847. PMC: 5919410. DOI: 10.1016/j.stemcr.2018.01.039. View

Liu Y, Steinbusch L, Nabben M, Kapsokalyvas D, van Zandvoort M, Schonleitner P . Palmitate-Induced Vacuolar-Type H-ATPase Inhibition Feeds Forward Into Insulin Resistance and Contractile Dysfunction. Diabetes. 2017; 66(6):1521-1534. DOI: 10.2337/db16-0727. View

Piga D, Salani S, Magri F, Brusa R, Mauri E, Comi G . Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies. Ther Adv Neurol Disord. 2019; 12:1756286419833478. PMC: 6501480. DOI: 10.1177/1756286419833478. View

Sarkar S, Trivedi D, Morck M, Adhikari A, Pasha S, Ruppel K . The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin. Sci Adv. 2020; 6(14):eaax0069. PMC: 7124958. DOI: 10.1126/sciadv.aax0069. View

Seeger T, Shrestha R, Lam C, Chen C, McKeithan W, Lau E . A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. Circulation. 2018; 139(6):799-811. PMC: 6443405. DOI: 10.1161/CIRCULATIONAHA.118.034624. View

10.

Liang P, Sallam K, Wu H, Li Y, Itzhaki I, Garg P . Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome. J Am Coll Cardiol. 2016; 68(19):2086-2096. PMC: 5373649. DOI: 10.1016/j.jacc.2016.07.779. View

11.

Eng G, Lee B, Protas L, Gagliardi M, Brown K, Kass R . Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes. Nat Commun. 2016; 7:10312. PMC: 4735644. DOI: 10.1038/ncomms10312. View

12.

Ribeiro A, Ang Y, Fu J, Rivas R, Mohamed T, Higgs G . Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc Natl Acad Sci U S A. 2015; 112(41):12705-10. PMC: 4611612. DOI: 10.1073/pnas.1508073112. View

13.

Yang X, Papoian T . Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. J Appl Toxicol. 2018; 38(9):1166-1176. DOI: 10.1002/jat.3611. View

14.

Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez O . Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012; 4(130):130ra47. PMC: 3657516. DOI: 10.1126/scitranslmed.3003552. View

15.

Prigozhina N, Heisel A, Wei K, Noberini R, Hunter E, Calzolari D . Characterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening. Biol Cell. 2011; 103(10):467-81. PMC: 3538155. DOI: 10.1042/BC20100146. View

16.

Cerignoli F, Charlot D, Whittaker R, Ingermanson R, Gehalot P, Savchenko A . High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J Pharmacol Toxicol Methods. 2012; 66(3):246-56. PMC: 3667588. DOI: 10.1016/j.vascn.2012.08.167. View

17.

Fellmann C, Gowen B, Lin P, Doudna J, Corn J . Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2016; 16(2):89-100. PMC: 5459481. DOI: 10.1038/nrd.2016.238. View

18.

Sakamoto K, Sakatoku K, Sugimoto S, Iwasaki N, Sano Y, Yamaguchi M . Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects. J Pharmacol Sci. 2019; 140(4):345-349. DOI: 10.1016/j.jphs.2019.08.005. View

19.

Garg P, Oikonomopoulos A, Chen H, Li Y, Lam C, Sallam K . Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant. J Am Coll Cardiol. 2018; 72(1):62-75. PMC: 6050025. DOI: 10.1016/j.jacc.2018.04.041. View

20.

Friedman C, Nguyen Q, Lukowski S, Helfer A, Chiu H, Miklas J . Single-Cell Transcriptomic Analysis of Cardiac Differentiation from Human PSCs Reveals HOPX-Dependent Cardiomyocyte Maturation. Cell Stem Cell. 2018; 23(4):586-598.e8. PMC: 6220122. DOI: 10.1016/j.stem.2018.09.009. View